BioLingus is an award-winning Swiss biotech company spearheading the development of oral (sublingual) and mucosal delivery of peptides and proteins. BioLingus believes they can make life better for many people in the world, not just in rich countries, but across the globe.

BioLingus’ technology is “inspired by nature” using applied bio-engineering, resulting in novel bio-mimetic materials for drug delivery and it focuses on the development of its own products on the treatment of chronic diseases, such as diabetes, obesity and inflammatory diseases.

BioLingus’ main office is in Switzerland, with satellite companies in Hong Kong and Australia. BioLingus receives Award for “Best European Biotech Company 2018”
and it is also a proud winner of the 2018 Red Herring Top100 Award.  As such, BioLingus can “broaden access” for patients in third world countries, which is an important goal for WHO.

For more information about this company, please click here.